SCHEMBL11076557

SCHEMBL11076557

COC(=O)C1C=CC(=O)C=C1

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DNTT P04053 3/20 0.37
POLB P06746 3/20 0.35
POLA1 P09884 1/20 0.35
ALDH1A1 P00352 2/20 0.34
KMT2A Q03164 2/20 0.33
BRD4 O60885 1/20 0.33
SETD7 Q8WTS6 1/20 0.32
CYP1A2 P05177 1/20 0.32
HIF1A Q16665 1/20 0.32
MIF P14174 1/20 0.31
HTT P42858 1/20 0.31
CA1 P00915 1/20 0.31
CA2 P00918 1/20 0.31
CA4 P22748 1/20 0.31
CA7 P43166 1/20 0.31
BCHE P06276 1/20 0.30
MAOA P21397 1/20 0.30
ACHE P22303 1/20 0.30
MAOB P27338 1/20 0.30
APEX1 P27695 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7035623 0.98 DNTT (0.36) DNTTPOLBPOLA1ALDH1A1KMT2A
SCHEMBL8709284 0.80
SCHEMBL12494483 0.80 CYP2C19 (0.39) POLBALDH1A1HTTTDP1
SCHEMBL12467437 0.77 DNTT (0.31) DNTTPOLB
SCHEMBL19346720 0.75
SCHEMBL27590444 0.73 ALDH1A1 (0.33) POLBALDH1A1BRD4CYP1A2MAPK1
SCHEMBL28750893 0.73 ALDH1A1 (0.33) POLBALDH1A1BRD4CYP1A2MAPK1
SCHEMBL27608813 0.73 ALDH1A1 (0.33) POLBALDH1A1BRD4CYP1A2MAPK1
SCHEMBL12870314 0.73 ALDH1A1 (0.33) POLBALDH1A1BRD4CYP1A2MAPK1
SCHEMBL17778591 0.73 MIF (0.39) POLBALDH1A1MIFBCHEMAOA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20210061762-A1 P300/CBP HAT INHIBITORS CONSTELLATION PHARMACEUTICALS, INC. 2021-03-04 US disclosed
EP-3752250-A1 P300/CBP HAT INHIBITORS Constellation Pharmaceuticals, Inc. (US) 2020-12-23 EP disclosed
WO-2019161157-A1 P300/CBP HAT INHIBITORS CONSTELLATION PHARMCEUTICALS, INC. (US) 2019-08-22 WO disclosed
US-4460583-A ANTIBIOTIC, BACTERICIDE FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 1984-07-17 US disclosed
US-4393059-A BACTERICIDAL CEPHALOSPORINS FUJISAWA PHARMACEUTICAL COMPANY, LIMITED (JP) 1983-07-12 US disclosed
US-4294960-A 7-[2-(2-Aminothiazol-4-yl)-2-cyclopentyloxyiminoacetamido]-3-cephem-4-carboxylic acid (synisomer) FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 1981-10-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210061762-A1 P300/CBP HAT INHIBITORS EP300, HDAC1, KAT2A DNTT 931/4885POLB 1082/4885POLA1 671/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.